TW200745130A - 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists - Google Patents

2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Info

Publication number: TW200745130A
Authority: TW; Taiwan
Prior art keywords: heteroaryl; triazolo; pyrazolo; receptor antagonists; optionally substituted
Prior art date: 2005-09-19

Application number

TW095134460A

Other languages

English (en)

Inventor

Bernard R Neustadt

Craig Boyle

Samuel Chackalamannil

Joel Harris

Claire Lankin

Hong Liu

Unmesh Shah

Andrew W Stamford

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-19

Filing date

2006-09-18

Publication date

2007-12-16

2006-09-18 Application filed by Schering Corp filed Critical Schering Corp

2007-12-16 Publication of TW200745130A publication Critical patent/TW200745130A/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
Neurology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Psychiatry (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TW095134460A 2005-09-19 2006-09-18 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists TW200745130A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US71850205P	2005-09-19	2005-09-19

Publications (1)

Publication Number	Publication Date
TW200745130A true TW200745130A (en)	2007-12-16

Family

ID=37671403

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095134460A TW200745130A (en)	2005-09-19	2006-09-18	2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Country Status (9)

Country	Link
US (1)	US7465740B2 (zh)
EP (1)	EP1934227B1 (zh)
JP (1)	JP2009508871A (zh)
CN (1)	CN101312978A (zh)
AR (1)	AR057817A1 (zh)
AT (1)	ATE538123T1 (zh)
CA (1)	CA2622741A1 (zh)
TW (1)	TW200745130A (zh)
WO (1)	WO2007035542A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK287748B6 (sk) *	2000-05-26	2011-08-04	Schering Corporation	Substituované 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo[1,5- c]pyrimidíny, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
WO2006132275A1 (ja) *	2005-06-07	2006-12-14	Kyowa Hakko Kogyo Co., Ltd.	運動障害の予防および／または治療剤
MX2009000104A (es) *	2006-06-26	2009-01-23	Schering Corp	Antagonistas del receptor de adenosina a2a.
US7723343B2 (en) *	2007-03-30	2010-05-25	King Pharmaceuticals Research And Development, Inc.	Adenosine A2A receptor antagonists
AU2009222047A1 (en)	2008-03-04	2009-09-11	Schering Corporation	1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine A2a receptor antagonists
TW201100427A (en) *	2009-03-31	2011-01-01	Arqule Inc	Substituted heterocyclic compounds
WO2011101861A1 (en)	2010-01-29	2011-08-25	Msn Laboratories Limited	Process for preparation of dpp-iv inhibitors
JP5843869B2 (ja) *	2010-09-24	2016-01-13	アドヴィナス・セラピューティックス・リミテッド	アデノシン受容体拮抗薬としての縮合三環化合物
WO2020106558A1 (en)	2018-11-20	2020-05-28	Merck Sharp & Dohme Corp.	Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020106560A1 (en)	2018-11-20	2020-05-28	Merck Sharp & Dohme Corp.	Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
JOP20210116A1 (ar)	2018-11-30	2023-01-30	Merck Sharp & Dohme	مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها
JP2022511778A (ja)	2018-11-30	2022-02-01	メルク・シャープ・アンド・ドーム・コーポレーション	アデノシン受容体拮抗薬としての７－、８－及び１０－置換されたアミノトリアゾロキナゾリン誘導体、医薬組成物及びそれらの使用
CN110240571A (zh) *	2019-06-12	2019-09-17	天津药明康德新药开发有限公司	乙基-5-Boc-氨基-4,5,6,7-四氢苯并[d]异恶唑-3-羧酸酯的制法
US20230024108A1 (en) *	2019-07-17	2023-01-26	Teon Therapeutics, Inc.	Adenosine a2a receptor antagonists
CN111072675A (zh) *	2019-12-12	2020-04-28	广东东阳光药业有限公司	含氮稠合三环衍生物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1264901B1 (it)	1993-06-29	1996-10-17	Schering Plough S P A	Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
ATE208199T1 (de) *	1993-07-27	2001-11-15	Kyowa Hakko Kogyo Kk	Arzneimittel gegen parkinsonsche krankheit
IT1277392B1 (it)	1995-07-28	1997-11-10	Schering Plough S P A	Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it)	1997-05-21	1999-01-07	Schering Plough S P A	Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
SK287748B6 (sk) *	2000-05-26	2011-08-04	Schering Corporation	Substituované 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo[1,5- c]pyrimidíny, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
GB0100624D0 (en)	2001-01-10	2001-02-21	Vernalis Res Ltd	Chemical compounds VII
EP1435960B1 (en) *	2001-10-15	2014-07-30	Merck Sharp & Dohme Corp.	Imidazo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as adenosine a2a receptor antagonists
WO2003101455A2 (en) *	2002-05-30	2003-12-11	King Pharmaceuticals Research & Development, Inc.	Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
NZ540493A (en)	2002-12-19	2008-04-30	Schering Corp	Uses of adenosine A2a receptor antagonists
TWI355381B (en)	2003-04-23	2012-01-01	Schering Corp	2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-tri
ATE461932T1 (de) *	2004-04-21	2010-04-15	Schering Corp	Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors

2006
- 2006-09-15 WO PCT/US2006/036127 patent/WO2007035542A1/en not_active Ceased
- 2006-09-15 AT AT06803715T patent/ATE538123T1/de active
- 2006-09-15 AR ARP060104050A patent/AR057817A1/es not_active Application Discontinuation
- 2006-09-15 US US11/522,221 patent/US7465740B2/en active Active
- 2006-09-15 JP JP2008531381A patent/JP2009508871A/ja active Pending
- 2006-09-15 EP EP06803715A patent/EP1934227B1/en active Active
- 2006-09-15 CA CA002622741A patent/CA2622741A1/en not_active Abandoned
- 2006-09-15 CN CNA2006800431754A patent/CN101312978A/zh active Pending
- 2006-09-18 TW TW095134460A patent/TW200745130A/zh unknown

Also Published As

Publication number	Publication date
WO2007035542A1 (en)	2007-03-29
AR057817A1 (es)	2007-12-19
US20070066620A1 (en)	2007-03-22
CA2622741A1 (en)	2007-03-29
EP1934227A1 (en)	2008-06-25
US7465740B2 (en)	2008-12-16
CN101312978A (zh)	2008-11-26
EP1934227B1 (en)	2011-12-21
ATE538123T1 (de)	2012-01-15
JP2009508871A (ja)	2009-03-05

Similar Documents

Publication	Publication Date	Title
TW200745130A (en)	2007-12-16	2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
ATE457988T1 (de)	2010-03-15	A2a-adenosin-rezeptor-antagonisten
WO2004094431A3 (en)	2004-12-02	2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
WO2007120752A3 (en)	2008-05-08	4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders
BRPI0611095B8 (pt)	2021-05-25	compostos inibidores de pde1, composição farmacêutica compreendendo-os, usos dos mesmos como inibidores de pde1 para o tratamento de doenças relacionadas, tal como doença de parkinson e deficiência cognitiva, e métodos para produção dos ditos compostos
MY146474A (en)	2012-08-15	Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
TW200613305A (en)	2006-05-01	Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
NZ596301A (en)	2014-10-31	Novel 7-deazapurine nucleosides for therapeutic uses
ATE424402T1 (de)	2009-03-15	Imidazopyridinverbindungen
LU92602I2 (fr)	2015-10-27	Trametinib, optionnellement sous la forme d'un sel, hydrate ou solvate pharmaceutiquement acceptablede celui-ci
IL182893A0 (en)	2007-08-19	PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
MX2009006700A (es)	2009-06-30	Derivados de 5-ciano-4-(pirolo)[2,3b]piridina-3-il)-pirimidinas utiles como inhibidores de proteina-cinasas.
NZ522326A (en)	2006-03-31	Adenosine A2A receptor antagonists
MX2010006748A (es)	2010-08-18	Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
WO2007095223A3 (en)	2010-06-24	Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
GEP20156417B (en)	2015-12-25	Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
WO2008070313A3 (en)	2008-11-20	3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
WO2008023362A3 (en)	2008-07-03	Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
MX2009010165A (es)	2009-10-12	Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
TW200730531A (en)	2007-08-16	7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5-amine
PT1869038E (pt)	2009-10-06	Compostos de 5,6,7,8-tetra-hidro-imidazo[1,2-a]piridin-2- ilamina substituída e sua utilização para produzir fármacos
BRPI0513287A (pt)	2008-05-06	derivados de pirido-pirimidina, sua preparação, sua aplicação em terapêutica
WO2006124996A3 (en)	2007-01-04	Inhibitors of polo-like kinase-1
TW200640904A (en)	2006-12-01	Quinazoline derivatives
MXPA05012772A (es)	2006-02-13	Derivados de benzotiazol y uso de los mismos en el tratamiento de enfermedades relacionadas con el receptor a2a de adenosina.